Yuezhe Li, Ph.D.

Research Scientist II

Yuezhe earned her Ph.D. in Biomedical Sciences from the University of Connecticut. Her thesis work aimed to understand molecular mechanisms that link diabetes with ciliopathy, a group of rare diseases. Other fields of experience include systems biology, machine learning, and mathematical modeling. More recently, she focused on developing physiologically based pharmacokinetic (PBPK) models to get a better mechanistic understanding of drugs’ pharmacokinetics.

Recent publications by this scientist

A Novel Agent-based Computational Model for Liver-targeting, AAV-based Gene Therapies Could Predict Response Durability in Hemophilia B Patients Treated with Etranacogene Dezaparvovec

May 19, 2025

Co-developed with CSL Behring, this research introduces a high-resolution model that simulates hepatocyte turnover, episomal retention and coagulation factor IX (FIX) expression in virtual patients treated with Etranacogene Dezaparvovec ( HEMGENIX). The model captured clinical variability before recent clinical readouts were available, and projects FIX expression durability over two decades.

Download PDF

Symbolic PBPK-PDE Modeling using Open-Source Julia Tools.

December 6, 2024

Presented at ACoP 2024. The poster introduces a framework for developing physiologically based pharmacokinetic (PBPK) models that incorporate partial differential equations (PDEs) to account for spatial drug distribution, using open-source Julia tools. This approach simplifies the integration of spatial components into PBPK models, demonstrated through a case study on naphthalene diffusion, and is applicable to various pharmacometric models requiring spatial considerations, such as topical, inhaled, and antitumor therapies.

Download PDF

Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined with Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients with DLBCL.

December 6, 2024

Presented at ACoP 2024. This poster described a QSP model that predicted the efficacy of loncastuximab tesirine (an antibody-drug conjugate) and mosunetuzumab/ glofitamab (T cell engagers) combination therapy, following the protocol of ongoing LOTIS-7 clinical trial. The model predicted keeping patients on combination therapy for longer but reduced the loncastuximab tesirine per treatment cycle would yield more tumor volume reduction.

Download PDF